Atrophic Gastritis Predicts the Risk of Gastric Cancer

NCT06203327 | Recruiting DMC

• 1 other identifier: rjhy20230004
• Study Type: observational
• Target: 2,042
• Locations: 1 country
• Sites: 1

Brief Summary

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Conditions

Atrophic Gastritis

Keywords

Atrophic Gastritis; Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• early gastric neoplasm

  histological diagnosis of high-grade dysplasia, and adenocarcinoma.

  After the baseline endoscopy, participants were scheduled for surveillance endoscopies at years 3-5 for subjects with operative link on gastritis assessment (OLGA) 0-Ⅰ, at years 2-3 for subjects with OLGA II and 1 year for subjects with OLGA III-IV.

Study Arms (3)

OLGA 0-I

Other: Esophagogastroscopy (OLGA 0-Ⅰ)

OLGA II

Other: Esophagogastroscopy (OLGA II)

OLGA III-IV

Other: Esophagogastroscopy (OLGA III-IV)

Interventions

Esophagogastroscopy (OLGA 0-Ⅰ) OTHER

Surveillance endoscopies at years 3-5.

OLGA 0-I

Esophagogastroscopy (OLGA II) OTHER

Surveillance endoscopies at years 2-3.

OLGA II

Esophagogastroscopy (OLGA III-IV) OTHER

Surveillance endoscopies every year.

OLGA III-IV

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Chronic gastritis diagnosed by routine endoscopic screening

You may qualify if:

• Ability and willingness to participate in the study and to sign and give informed consent
• Biopsies were collected based on the recommendation of updated Sydney system

You may not qualify if:

• under 18 or over 80 years old
• history of gastrectomy
• severe systemic diseases or malignancy

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine: lead

Study Sites (1)

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, 200127, China

RECRUITING

MeSH Terms

Conditions

Gastritis, Atrophic; Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastritis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Stomach Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine

Study Record Dates

• First Submitted: December 25, 2023
• First Posted: January 12, 2024
• Study Start: December 15, 2023
• Primary Completion (Estimated): December 31, 2034
• Study Completion (Estimated): December 31, 2034
• Last Updated: December 30, 2024

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)